Edition:
United States

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

31.40USD
22 Nov 2017
Change (% chg)

$0.22 (+0.71%)
Prev Close
$31.18
Open
$31.30
Day's High
$31.70
Day's Low
$30.85
Volume
256,770
Avg. Vol
375,120
52-wk High
$55.94
52-wk Low
$28.02

Latest Key Developments (Source: Significant Developments)

Medicines Co names Fred Eshelman executive chairman
Wednesday, 15 Nov 2017 07:30am EST 

Nov 15 (Reuters) - Medicines Co -:The Medicines Company names Dr. Fred Eshelman as executive chairman; appoints Geno Germano to its board of directors.Medicines Co - ‍appointed FREDRIC N. ESHELMAN, company's current chairman of board, to newly created position of executive chairman​.Medicines Co - ‍appointments are effective immediately​.  Full Article

SymBio Pharmaceuticals says arbitration against The Medicines Company
Monday, 13 Nov 2017 01:50am EST 

Nov 13 (Reuters) - SymBio Pharmaceuticals Ltd <4582.T>:Says co initiated an arbitration against The Medicines Company (MDCO) on Oct. 11, under the rules of International Chamber of Commerce, seeking damages arising out of MDCO's repudiation of the license agreement entered into between the co and MDCO on October 5, 2015, for the exclusive rights to develop and commercialize the patient-controlled pain management drug "SyB P-1501" (or "IONSYS") in Japan.Says the co seeks damages of $82 million (about 9 billion yen).  Full Article

The Medicines Co and Alnylam Pharmaceuticals to start phase III clinical trials of inclisiran
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Medicines Co :The Medicines Company and Alnylam Pharmaceuticals announce initiation of phase III clinical trials of inclisiran.Medicines Co - ‍continues to expect that all of these trials will commence before end of 2017​.  Full Article

The Medicines Company reports third-quarter 2017 business and financial results
Wednesday, 25 Oct 2017 07:00am EDT 

Oct 25 (Reuters) - Medicines Co :The Medicines Company reports third-quarter 2017 business and financial results.Q3 GAAP loss per share $0.42 from continuing operations.Q3 earnings per share view $-1.44 -- Thomson Reuters I/B/E/S.Q3 adjusted non-GAAP loss per share $1.19 from continuing operations.Says ‍operations worldwide net revenue was $16.9 million in Q3 of 2017 compared to $37.6 million in Q3 of 2016​.Medicines Co - ‍continue to expect to announce a transaction to divest infectious disease business before end of year.Medicines Co - ‍independent of ID business transaction, finalizing plans to significantly restructure remainder of Medicines Company​.Medicines Co - ‍anticipate restructuring, intended to be substantially implemented in next 45 days, will reduce headcount to less than 60 people at Co.Q3 revenue view $24.4 million -- Thomson Reuters I/B/E/S.  Full Article

The Medicines Company announces FDA approval of Vabomere
Wednesday, 30 Aug 2017 07:00am EDT 

Aug 30 (Reuters) - Medicines Co :The Medicines Company announces FDA approval of Vabomere (meropenem and vaborbactam).Vabomere expected to be available in Q4 of 2017.  Full Article

Alnylam says ‍inclisiran phase III development program gearing up​
Monday, 28 Aug 2017 07:00am EDT 

Aug 28 (Reuters) - Alnylam Pharmaceuticals Inc :New, one-year data from orion-1 phase ii study of inclisiran extends excellent long-term efficacy and safety profile, affirming dose for phase iii trials.Alnylam pharmaceuticals inc - ‍inclisiran phase iii development program gearing up​.  Full Article

Medicines Co reports Q2 GAAP loss per share $5.52 from continuing operations
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Medicines Co :The Medicines Company reports second quarter 2017 business and financial results.Q2 GAAP loss per share $5.52 from continuing operations.Q2 revenue $18.7 million versus $54.7 million.Q2 earnings per share view $-1.96 -- Thomson Reuters I/B/E/S.Q2 revenue view $28.4 million -- Thomson Reuters I/B/E/S.Q2 adjusted non-GAAP loss per share $1.02 from continuing operations.  Full Article

The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam stopped early for superior benefit-risk compared to best available therapy for CRE
Tuesday, 25 Jul 2017 07:00am EDT 

July 25 (Reuters) - Medicines Co :The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE.Medicines Co - ‍company also announces vabomere (TM) as U.S. and European trade name for meropenem-vaborbactam​.Medicines Co - ‍trial stopped early following recommendation by independent data safety and monitoring board​.Medicines Co - will continue to enroll patients into an amended, single-arm study protocol for treatment with meropenem-vaborbactam at selected sites​.Medicines Co - ‍DSMB's recommendation to discontinue randomization into TANGO-2 trial was based on results of an interim analysis of data from TANGO-2​.Medicines Co - expects that data from TANGO-2 trial will be presented at a future medical conference and published in a peer-reviewed journal​.​.  Full Article

Medicines Co says commenced implementation of workforce reduction​
Friday, 2 Jun 2017 04:58pm EDT 

June 2 (Reuters) - Medicines Co ::Medicines Co - ‍on june 1, 2017, Medicines company commenced implementation of a workforce reduction​.Medicines - ‍workforce reduction will result in company reducing its personnel by approximately 60 employees​.Medicines - ‍workforce reduction representing approximately 15 pct of company's workforce - sec filing​.Medicines-‍expects to record pre-tax charge of about $270 million to $280 million associated with discontinuation and market withdrawal of Ionsys in U.S..Medicines - ‍company expects charges will be recognized in Q2 of 2017​.Medicines- expects to realize estimated annualized cost savings from voluntary discontinuation and market withdrawal of ionsys of approximately $35 million​.Medicines Co - ‍voluntary discontinuation and withdrawal from market of Ionsys is not due to any safety or product quality concerns​.Medicines-‍workforce reduction was in connection with discontinuation & market withdrawal of Ionsys in U.S., cessation of commercialization activities​.  Full Article

Medicines says U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor
Friday, 19 May 2017 05:09pm EDT 

May 19 (Reuters) - Medicines Co :Medicines-U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor.Medicines Co - Proposed settlement requires company to implement certain corporate governance measures - SEC Filing.Medicines Co - Proposed settlement requires co to pay certain attorneys' fees, expenses to plaintiff's counsel in an amount to be determined by court.  Full Article

BRIEF-Medicines Co names Fred Eshelman executive chairman

* The Medicines Company names Dr. Fred Eshelman as executive chairman; appoints Geno Germano to its board of directors